MYNDF (MYND Life Sciences) Change In Inventory : $0.00 Mil (TTM As of Apr. 2024)

View and export this data going back to 2021. Start your Free Trial

What is MYND Life Sciences Change In Inventory?

MYND Life Sciences's change in inventory for the quarter that ended in Apr. 2024 was $0.00 Mil. It means MYND Life Sciences's inventory stayed the same from Jan. 2024 to Apr. 2024 .

MYND Life Sciences's change in inventory for the fiscal year that ended in Oct. 2023 was $0.00 Mil. It means MYND Life Sciences's inventory stayed the same from Oct. 2022 to Oct. 2023 .

MYND Life Sciences's Total Inventories for the quarter that ended in Apr. 2024 was $0.00 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. MYND Life Sciences's Days Inventory for the quarter that ended in Apr. 2024 was 0.00.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

MYND Life Sciences Change In Inventory Historical Data

The historical data trend for MYND Life Sciences's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MYND Life Sciences Change In Inventory Chart

MYND Life Sciences Annual Data

Trend

Oct21

Oct22

Oct23

Change In Inventory

MYND Life Sciences Quarterly Data
	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24
Change In Inventory	Get a 7-Day Free Trial									-	-	-	-	-

MYND Life Sciences Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Apr. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

MYND Life Sciences (OTCPK:MYNDF) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

MYND Life Sciences's Days Inventory for the quarter that ended in is calculated as:

Days Inventory	=	Average Total Inventories	/	Cost of Goods Sold	*	Days in Period
	=	0	/	0.044	*	365 / 4
	=	0.00

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

MYND Life Sciences's Inventory Turnover for the quarter that ended in Apr. 2024 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	0.044	/	0
	=	N/A

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

MYND Life Sciences's Inventory to Revenue for the quarter that ended in Apr. 2024 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	0	/	0
	=	N/A

MYND Life Sciences Change In Inventory Related Terms

Thank you for viewing the detailed overview of MYND Life Sciences's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

MYND Life Sciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MYND Life Sciences Inc (OTCPK:MYNDF) » Definitions » Change In Inventory

Comparable Companies

Traded in Other Exchanges

MYND:Canada

Address

05-2248 Elgin Ave., Port Coquitlam, BC, CAN, V3C 2B2

Website

https://www.myndsciences.com

MYND Life Sciences Inc is a medical biotech drug research and development company. The company is focused on neuro pharmaceutical and novel drug development, diagnostics, and vaccines and is developing new biological entities (NBEs) and new chemical entities (NCEs) and differentiates itself from other (bio)pharmaceutical companies by different molecular concepts for the applications of psilocybin analogs for overcoming diseases.